GlassScriptPhysician profile
Andrew Lituchy
NPI 1740287010
$17,557.28
in general payments reported to CMS, 2019-2025
34 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,760 · 2020: $2,035 · 2021: $3,101 · 2022: $2,245 · 2023: $2,211 · 2024: $1,965 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,417.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,328.08 | 2019-2025 | Aveir, Assurity, Merlin@Home |
| Amgen INC. | $2,074.03 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $2,029.02 | 2021-2025 | Symplicity G3, Mosaic |
| Medtronic Vascular, INC. | $1,512.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,499.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $976.36 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $622.66 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $323.34 | 2019-2023 | Farxiga |
| Pfizer INC. | $306.32 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $268.05 | 2019 | |
| Novo Nordisk INC | $242.02 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Philips North America LLC | $215.30 | 2019 | |
| Shockwave Medical, INC | $202.52 | 2020-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Heartflow, INC. | $201.81 | 2023-2025 | Ffrct |
| Regeneron Healthcare Solutions, INC. | $187.23 | 2020-2024 | Evkeeza, Praluent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $177.92 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.70 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $158.90 | 2020-2022 | |
| Teleflex LLC | $158.72 | 2023 | Guideliner |
| Bayer Healthcare Pharmaceuticals INC. | $150.73 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $101.48 | 2024 | Arcalyst |
| Chiesi USA, INC. | $94.43 | 2019-2025 | Kengreal, Cleviprex |
| Cardiva Medical, INC. | $79.12 | 2025 | Cardiva Vascade 5f Vcs, Cardiva Vascade 6/7f Vcs |
| Inspire Medical Systems, INC. | $78.66 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $74.29 | 2022-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $56.62 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $51.61 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $48.70 | 2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $39.82 | 2021-2022 | |
| Cvrx, INC. | $31.77 | 2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $26.13 | 2023 | Assure Wcd |
| Glaxosmithkline, LLC. | $24.27 | 2025 | Arexvy, Shingrix |
| Vifor Pharma, INC. | $24.12 | 2019 | |
| Penumbra, INC. | $17.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lituchy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.